Liangliang Gao, Aiping Tan, Zehui Wang, Lei Wei, Xingshuang Wang
{"title":"奥利啶联合异丙酚用于无痛宫腔镜的有效剂量:一项前瞻性剂量发现研究。","authors":"Liangliang Gao, Aiping Tan, Zehui Wang, Lei Wei, Xingshuang Wang","doi":"10.2147/IJGM.S523428","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The combination of oliceridine with propofol represents a new option for complete intravenous anesthesia in painless hysteroscopy. The purpose of this study was to determine the 95% effective dose (ED95) and the median effective dose (ED50) of oliceridine when combined with propofol for painless hysteroscopy.</p><p><strong>Methods: </strong>A total of 29 patients, aged between 18 and 60 years and classified as American Society of Anesthesiologists (ASA) I-II, were initially recruited for hysteroscopy. Subsequently, 26 of these patients were included in the final analysis. Before surgery, an intravenous dose of 0.02 mg/kg oliceridine, with a dose gradient of 0.002 mg/kg, was administered using Dixon's up-and-down method. Two minutes later, 2 mg/kg of propofol was administered. The oliceridine dosage for the following patient was increased by 0.002 mg/kg if the hysteroscopy failed (defined as poor cervical dilatation, problematic hysteroscopic placement, or a Ramsay Sedation Scale (RSS) score < 5 or any movement and frowning by the patient within 5 minutes). In contrast, the dosage was decreased by 0.002 mg/kg. At least seven crossovers had to occur before the test was stopped. The ED50 and ED95 of oliceridine in combination with propofol for hysteroscopy were determined using the probit analysis method.</p><p><strong>Results: </strong>The ED50 and ED95 of oliceridine with 95% CI were 0.0192 (0.0183-0.0216) mg/kg and 0.0237 (0.0214-0.0415) mg/kg, respectively. No patients experienced significant adverse effects.</p><p><strong>Conclusion: </strong>The study determined that the ED50 and ED95 of oliceridine in combination with propofol for painless hysteroscopy are 0.0192 mg/kg and 0.0237 mg/kg, respectively. Oliceridine at 0.0237 mg/kg provides safe and effective anesthesia when combined with propofol.</p>","PeriodicalId":14131,"journal":{"name":"International Journal of General Medicine","volume":"18 ","pages":"2651-2657"},"PeriodicalIF":2.1000,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12104668/pdf/","citationCount":"0","resultStr":"{\"title\":\"Effective Doses of Oliceridine Combined with Propofol for Painless Hysteroscopy: A Prospective Dose-Finding Study.\",\"authors\":\"Liangliang Gao, Aiping Tan, Zehui Wang, Lei Wei, Xingshuang Wang\",\"doi\":\"10.2147/IJGM.S523428\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>The combination of oliceridine with propofol represents a new option for complete intravenous anesthesia in painless hysteroscopy. The purpose of this study was to determine the 95% effective dose (ED95) and the median effective dose (ED50) of oliceridine when combined with propofol for painless hysteroscopy.</p><p><strong>Methods: </strong>A total of 29 patients, aged between 18 and 60 years and classified as American Society of Anesthesiologists (ASA) I-II, were initially recruited for hysteroscopy. Subsequently, 26 of these patients were included in the final analysis. Before surgery, an intravenous dose of 0.02 mg/kg oliceridine, with a dose gradient of 0.002 mg/kg, was administered using Dixon's up-and-down method. Two minutes later, 2 mg/kg of propofol was administered. The oliceridine dosage for the following patient was increased by 0.002 mg/kg if the hysteroscopy failed (defined as poor cervical dilatation, problematic hysteroscopic placement, or a Ramsay Sedation Scale (RSS) score < 5 or any movement and frowning by the patient within 5 minutes). In contrast, the dosage was decreased by 0.002 mg/kg. At least seven crossovers had to occur before the test was stopped. The ED50 and ED95 of oliceridine in combination with propofol for hysteroscopy were determined using the probit analysis method.</p><p><strong>Results: </strong>The ED50 and ED95 of oliceridine with 95% CI were 0.0192 (0.0183-0.0216) mg/kg and 0.0237 (0.0214-0.0415) mg/kg, respectively. No patients experienced significant adverse effects.</p><p><strong>Conclusion: </strong>The study determined that the ED50 and ED95 of oliceridine in combination with propofol for painless hysteroscopy are 0.0192 mg/kg and 0.0237 mg/kg, respectively. Oliceridine at 0.0237 mg/kg provides safe and effective anesthesia when combined with propofol.</p>\",\"PeriodicalId\":14131,\"journal\":{\"name\":\"International Journal of General Medicine\",\"volume\":\"18 \",\"pages\":\"2651-2657\"},\"PeriodicalIF\":2.1000,\"publicationDate\":\"2025-05-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12104668/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of General Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2147/IJGM.S523428\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of General Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/IJGM.S523428","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
Effective Doses of Oliceridine Combined with Propofol for Painless Hysteroscopy: A Prospective Dose-Finding Study.
Background: The combination of oliceridine with propofol represents a new option for complete intravenous anesthesia in painless hysteroscopy. The purpose of this study was to determine the 95% effective dose (ED95) and the median effective dose (ED50) of oliceridine when combined with propofol for painless hysteroscopy.
Methods: A total of 29 patients, aged between 18 and 60 years and classified as American Society of Anesthesiologists (ASA) I-II, were initially recruited for hysteroscopy. Subsequently, 26 of these patients were included in the final analysis. Before surgery, an intravenous dose of 0.02 mg/kg oliceridine, with a dose gradient of 0.002 mg/kg, was administered using Dixon's up-and-down method. Two minutes later, 2 mg/kg of propofol was administered. The oliceridine dosage for the following patient was increased by 0.002 mg/kg if the hysteroscopy failed (defined as poor cervical dilatation, problematic hysteroscopic placement, or a Ramsay Sedation Scale (RSS) score < 5 or any movement and frowning by the patient within 5 minutes). In contrast, the dosage was decreased by 0.002 mg/kg. At least seven crossovers had to occur before the test was stopped. The ED50 and ED95 of oliceridine in combination with propofol for hysteroscopy were determined using the probit analysis method.
Results: The ED50 and ED95 of oliceridine with 95% CI were 0.0192 (0.0183-0.0216) mg/kg and 0.0237 (0.0214-0.0415) mg/kg, respectively. No patients experienced significant adverse effects.
Conclusion: The study determined that the ED50 and ED95 of oliceridine in combination with propofol for painless hysteroscopy are 0.0192 mg/kg and 0.0237 mg/kg, respectively. Oliceridine at 0.0237 mg/kg provides safe and effective anesthesia when combined with propofol.
期刊介绍:
The International Journal of General Medicine is an international, peer-reviewed, open access journal that focuses on general and internal medicine, pathogenesis, epidemiology, diagnosis, monitoring and treatment protocols. The journal is characterized by the rapid reporting of reviews, original research and clinical studies across all disease areas.
A key focus of the journal is the elucidation of disease processes and management protocols resulting in improved outcomes for the patient. Patient perspectives such as satisfaction, quality of life, health literacy and communication and their role in developing new healthcare programs and optimizing clinical outcomes are major areas of interest for the journal.
As of 1st April 2019, the International Journal of General Medicine will no longer consider meta-analyses for publication.